» Articles » PMID: 15467532

Oral Contraceptive Use, Reproductive History, and Risk of Epithelial Ovarian Cancer in Women with and Without Endometriosis

Overview
Publisher Elsevier
Date 2004 Oct 7
PMID 15467532
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Women with endometriosis may be at an increased risk of ovarian cancer. It is not known whether reproductive factors that reduce the risk of ovarian cancer in general also reduce risk in women with endometriosis. We investigated whether the odds ratios for ovarian cancer that were associated with oral contraceptive use, childbearing, hysterectomy, and tubal ligation differ among women with and without endometriosis.

Study Design: We pooled information on the self-reported history of endometriosis from 4 population-based case-controlled studies of incident epithelial ovarian cancer, comprising 2098 cases and 2953 control subjects. We obtained data on oral contraceptive use, childbearing, breastfeeding, gynecologic surgical procedures, and other reproductive factors on each woman. Multivariable unconditional logistic regression was used to calculate odds ratios and 95% CI for ovarian cancer among women with endometriosis compared with women without endometriosis. Similar methods were used to assess the frequencies of risk factors among women with and without endometriosis. Adjustments were made for age, parity, oral contraceptive use, tubal ligation, family history of ovarian cancer, and study site.

Results: Women with endometriosis were at an increased risk of ovarian cancer (odds ratio, 1.32; 95% CI, 1.06-1.65). Using oral contraceptives, bearing children, and having a tubal ligation or hysterectomy were associated with a similar reduction in the odds ratios for ovarian cancer among women with and without endometriosis. In particular, the use of oral contraceptives for >10 years was associated with a substantial reduction in risk among women with endometriosis (odds ratio, 0.21; 95% CI, 0.08-0.58).

Conclusion: Women with endometriosis are at an increased risk of epithelial ovarian cancer. Long-term oral contraceptive use may provide substantial protection against the disease in this high-risk population.

Citing Articles

C-Reactive Protein/Albumin Ratio and Clinicopathological Features in Ovarian Cancer: A Prospective Study.

Barik A, Rashmi A, Singh V, Upadhyay A Cureus. 2025; 16(12):e76542.

PMID: 39877772 PMC: 11772093. DOI: 10.7759/cureus.76542.


The long road of drug development for endometriosis - Pains, gains, and hopes.

Liao Z, Monsivais D, Matzuk M J Control Release. 2024; 376:429-440.

PMID: 39427778 PMC: 11884332. DOI: 10.1016/j.jconrel.2024.10.036.


Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.

Steinbuch S, Luss A, Eltrop S, Gotte M, Kiesel L Int J Mol Sci. 2024; 25(8).

PMID: 38673891 PMC: 11050613. DOI: 10.3390/ijms25084306.


Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions.

Vercellini P, Bandini V, Vigano P, Ambruoso D, Cetera G, Somigliana E Hum Reprod. 2023; 39(1):18-34.

PMID: 37951241 PMC: 11639102. DOI: 10.1093/humrep/dead206.


Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators-a review.

Dinca A, Diaconu A, Birla R, Coculescu B, Dinca V, Manole G Int J Immunopathol Pharmacol. 2023; 37:3946320231178769.

PMID: 37246293 PMC: 10226927. DOI: 10.1177/03946320231178769.